• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Contemporary Concise Review 2021: COVID-19 and other respiratory infections.当代简明综述 2021 年版:COVID-19 与其他呼吸道感染。
Respirology. 2022 Aug;27(8):661-668. doi: 10.1111/resp.14305. Epub 2022 Jun 7.
2
Human and novel coronavirus infections in children: a review.儿童人感染和新型冠状病毒感染:综述。
Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25.
3
[Respiratory virus infections after hematopoietic cell transplantation].造血细胞移植后的呼吸道病毒感染
Rinsho Ketsueki. 2021;62(8):1288-1295. doi: 10.11406/rinketsu.62.1288.
4
Surveillance Metrics of SARS-CoV-2 Transmission in Central Asia: Longitudinal Trend Analysis.中亚地区 SARS-CoV-2 传播的监测指标:纵向趋势分析。
J Med Internet Res. 2021 Feb 3;23(2):e25799. doi: 10.2196/25799.
5
COVID-19: a conundrum to decipher.COVID-19:一个待破译的谜。
Eur Rev Med Pharmacol Sci. 2020 May;24(10):5830-5841. doi: 10.26355/eurrev_202005_21378.
6
Aerosol transmission of SARS-CoV-2 by children and adults during the COVID-19 pandemic.新冠疫情期间儿童和成人通过气溶胶传播 SARS-CoV-2。
Pediatr Pulmonol. 2021 Jun;56(6):1389-1394. doi: 10.1002/ppul.25330. Epub 2021 Mar 15.
7
Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.重新利用治疗方法以潜在治疗 SARS-CoV-2:综述。
Viruses. 2020 Jun 30;12(7):705. doi: 10.3390/v12070705.
8
The Coronavirus Pandemic: What Does the Evidence Show?新冠疫情:证据表明了什么?
J Nepal Health Res Counc. 2020 Apr 19;18(1):1-9. doi: 10.33314/jnhrc.v18i1.2596.
9
Characteristics and management of asymptomatic SARS-CoV-2 infections.无症状 SARS-CoV-2 感染的特征和管理。
J Basic Clin Physiol Pharmacol. 2021 Sep 13;33(1):1-7. doi: 10.1515/jbcpp-2021-0159.
10
The Ineluctable Role of ACE-2 Receptors in SARS COV-2 Infection and Drug Repurposing as a Plausible SARS COV-2 Therapy: A Concise Treatise.ACE2 受体在 SARS-CoV-2 感染中的必然作用及药物再利用作为 SARS-CoV-2 治疗的合理策略:简明论述。
Curr Mol Med. 2021;21(10):888-913. doi: 10.2174/1573405617666210204212024.

本文引用的文献

1
Circulation of Non-SARS-CoV-2 Respiratory Pathogens and Coinfection with SARS-CoV-2 Amid the COVID-19 Pandemic.2019冠状病毒病大流行期间非严重急性呼吸综合征冠状病毒2型呼吸道病原体的传播及与严重急性呼吸综合征冠状病毒2型的合并感染
Open Forum Infect Dis. 2021 Dec 8;9(3):ofab618. doi: 10.1093/ofid/ofab618. eCollection 2022 Mar.
2
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.巴瑞替尼联合标准治疗对接受有创机械通气或体外膜肺氧合治疗的 COVID-19 重症住院成年患者的疗效和安全性:一项探索性、随机、安慰剂对照试验。
Lancet Respir Med. 2022 Apr;10(4):327-336. doi: 10.1016/S2213-2600(22)00006-6. Epub 2022 Feb 3.
3
Predictors of the Development of Protracted Bacterial Bronchitis following Presentation to Healthcare for an Acute Respiratory Illness with Cough: Analysis of Three Cohort Studies.因咳嗽急性呼吸道疾病就医后发生迁延性细菌性支气管炎的预测因素:三项队列研究分析
J Clin Med. 2021 Dec 7;10(24):5735. doi: 10.3390/jcm10245735.
4
Longitudinal Cytokine Profile in Patients With Mild to Critical COVID-19.轻度至危重新冠肺炎患者的纵向细胞因子特征。
Front Immunol. 2021 Dec 6;12:763292. doi: 10.3389/fimmu.2021.763292. eCollection 2021.
5
Factors associated with prolonged duration of viral clearance in non-severe SARS-CoV-2 patients in Osaka, Japan.与日本大阪非重症 SARS-CoV-2 患者病毒清除时间延长相关的因素。
Environ Health Prev Med. 2021 Dec 6;26(1):115. doi: 10.1186/s12199-021-01035-y.
6
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.在英国,用 ChAdOx1 nCov-19 或 BNT162b2 接种两剂后作为第三剂(加强针)接种 7 种 COVID-19 疫苗的安全性和免疫原性(COV-BOOST):一项盲法、多中心、随机、对照、2 期试验。
Lancet. 2021 Dec 18;398(10318):2258-2276. doi: 10.1016/S0140-6736(21)02717-3. Epub 2021 Dec 2.
7
Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): A systematic review and meta-analysis.巴瑞替尼治疗 2019 冠状病毒病(COVID-19)的临床疗效和不良事件:系统评价和荟萃分析。
J Med Virol. 2022 Apr;94(4):1523-1534. doi: 10.1002/jmv.27482. Epub 2021 Dec 13.
8
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.BNT162b2和mRNA-1273新冠疫苗在卡塔尔针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)德尔塔变种的有效性
Nat Med. 2021 Dec;27(12):2136-2143. doi: 10.1038/s41591-021-01583-4. Epub 2021 Nov 2.
9
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.COVID-19 住院患者中应用秋水仙碱(RECOVERY):一项随机、对照、开放标签、平台试验。
Lancet Respir Med. 2021 Dec;9(12):1419-1426. doi: 10.1016/S2213-2600(21)00435-5. Epub 2021 Oct 18.
10
Nontuberculous mycobacterial lung disease caused by complex - disease burden, unmet needs, and advances in treatment developments.非结核分枝杆菌肺病由复杂疾病负担、未满足的需求以及治疗进展引起。
Expert Rev Respir Med. 2021 Nov;15(11):1387-1401. doi: 10.1080/17476348.2021.1987891. Epub 2021 Oct 18.

当代简明综述 2021 年版:COVID-19 与其他呼吸道感染。

Contemporary Concise Review 2021: COVID-19 and other respiratory infections.

机构信息

Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong.

Stanley Ho Center for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong.

出版信息

Respirology. 2022 Aug;27(8):661-668. doi: 10.1111/resp.14305. Epub 2022 Jun 7.

DOI:10.1111/resp.14305
PMID:35670259
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9347613/
Abstract

Bats are likely the primary source of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Minks are highly susceptible to infection by SARS-CoV-2. Transmission from asymptomatic individuals was estimated to account for over 50% of all transmissions of coronavirus disease 2019 (COVID-19) cases. SARS-CoV-2 is evolving towards more efficient aerosol transmission. Remdesivir, baricitinib, tocilizumab and dexamethasone are frequently used for the treatment of patients with respiratory failure due to COVID-19. There is a rising incidence of non-tuberculous Mycobacterium pulmonary disease globally, with a higher prevalence in Asian countries than in the Western world. Protracted bacterial bronchitis is a common cause of chronic productive cough in childhood. Re-emergence of respiratory syncytial virus may occur after the relaxation of infection control measures and the reopening of borders during COVID-19 pandemic.

摘要

蝙蝠可能是严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的主要来源。水貂极易感染 SARS-CoV-2。无症状感染者的传播估计占所有 2019 年冠状病毒病(COVID-19)病例传播的 50%以上。SARS-CoV-2 正朝着更有效的气溶胶传播方向进化。瑞德西韦、巴瑞替尼、托珠单抗和地塞米松常用于治疗因 COVID-19 导致呼吸衰竭的患者。全球非结核分枝杆菌肺病的发病率正在上升,亚洲国家的患病率高于西方国家。迁延性细菌性支气管炎是儿童慢性湿性咳嗽的常见原因。呼吸道合胞病毒在 COVID-19 大流行期间感染控制措施放松和边境重新开放后可能会再次出现。